JP2008524260A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008524260A5 JP2008524260A5 JP2007547045A JP2007547045A JP2008524260A5 JP 2008524260 A5 JP2008524260 A5 JP 2008524260A5 JP 2007547045 A JP2007547045 A JP 2007547045A JP 2007547045 A JP2007547045 A JP 2007547045A JP 2008524260 A5 JP2008524260 A5 JP 2008524260A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- haloalkyl
- acceptable salt
- cycloalkyl
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 12
- -1 1-hydroxycyclopentyl Chemical group 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 125000000355 1,3-benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 208000001132 Osteoporosis Diseases 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 5
- 125000006729 (C2-C5) alkenyl group Chemical group 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 3
- 150000002148 esters Chemical class 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 3
- 206010036790 Productive cough Diseases 0.000 claims 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims 2
- 210000003491 skin Anatomy 0.000 claims 2
- 210000003802 sputum Anatomy 0.000 claims 2
- 208000024794 sputum Diseases 0.000 claims 2
- 125000006726 (C1-C5) alkenyl group Chemical group 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 229940122361 Bisphosphonate Drugs 0.000 claims 1
- 208000010392 Bone Fractures Diseases 0.000 claims 1
- 241000219198 Brassica Species 0.000 claims 1
- 235000003351 Brassica cretica Nutrition 0.000 claims 1
- 235000003343 Brassica rupestris Nutrition 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102000055006 Calcitonin Human genes 0.000 claims 1
- 108060001064 Calcitonin Proteins 0.000 claims 1
- 208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010017076 Fracture Diseases 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 229930003316 Vitamin D Natural products 0.000 claims 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 239000003098 androgen Substances 0.000 claims 1
- 229940030486 androgens Drugs 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 claims 1
- 150000004663 bisphosphonates Chemical class 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims 1
- 229960004015 calcitonin Drugs 0.000 claims 1
- 229940069978 calcium supplement Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000002113 chemopreventative effect Effects 0.000 claims 1
- 239000011280 coal tar Substances 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940011871 estrogen Drugs 0.000 claims 1
- 239000000262 estrogen Substances 0.000 claims 1
- 125000004494 ethyl ester group Chemical group 0.000 claims 1
- 150000002222 fluorine compounds Chemical class 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 230000035876 healing Effects 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000005020 hydroxyalkenyl group Chemical group 0.000 claims 1
- 125000005016 hydroxyalkynyl group Chemical group 0.000 claims 1
- 208000030915 hypercalcemia disease Diseases 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 claims 1
- 206010023332 keratitis Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 150000004702 methyl esters Chemical class 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 235000010460 mustard Nutrition 0.000 claims 1
- 208000005368 osteomalacia Diseases 0.000 claims 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 201000006409 renal osteodystrophy Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 229960004889 salicylic acid Drugs 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 210000004927 skin cell Anatomy 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 239000003451 thiazide diuretic agent Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 235000019166 vitamin D Nutrition 0.000 claims 1
- 239000011710 vitamin D Substances 0.000 claims 1
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 1
- 229940046008 vitamin d Drugs 0.000 claims 1
- 0 CCC(CC)(c1nc(ccc(C(N(C)C)=O)c2)c2[o]1)c(cc1C)ccc1OC(*C1(C)C)C1(C)O Chemical compound CCC(CC)(c1nc(ccc(C(N(C)C)=O)c2)c2[o]1)c(cc1C)ccc1OC(*C1(C)C)C1(C)O 0.000 description 24
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63802904P | 2004-12-21 | 2004-12-21 | |
| PCT/US2005/046361 WO2006069154A2 (en) | 2004-12-21 | 2005-12-19 | Vitamin d receptor modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008524260A JP2008524260A (ja) | 2008-07-10 |
| JP2008524260A5 true JP2008524260A5 (https=) | 2009-02-19 |
Family
ID=36602286
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007547045A Withdrawn JP2008524260A (ja) | 2004-12-21 | 2005-12-19 | ビタミンｄ受容体モジュレーター |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7659296B2 (https=) |
| EP (1) | EP1836177B1 (https=) |
| JP (1) | JP2008524260A (https=) |
| KR (1) | KR100931777B1 (https=) |
| AT (1) | ATE519755T1 (https=) |
| BR (1) | BRPI0519152A2 (https=) |
| CA (1) | CA2589667A1 (https=) |
| ES (1) | ES2369510T3 (https=) |
| IL (1) | IL183779A0 (https=) |
| MX (1) | MX2007007225A (https=) |
| WO (1) | WO2006069154A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1511740T1 (sl) | 2002-05-29 | 2009-12-31 | Lilly Co Eli | Modulatorji vitamin d receptorja tipa fenil-tiofen |
| DE60326082D1 (de) | 2002-11-22 | 2009-03-19 | Lilly Co Eli | Modulatoren von vitamin d rezeptoren |
| ES2291981T3 (es) | 2003-11-20 | 2008-03-01 | Eli Lilly And Company | Moduladores del receptor de la vitamina d. |
| US7595345B2 (en) | 2003-11-20 | 2009-09-29 | Eli Lilly And Company | Vitamin D receptor modulators |
| CA2544857A1 (en) | 2003-11-20 | 2005-06-09 | Eli Lilly And Company | Vitamin d receptor modulators |
| WO2005051898A2 (en) | 2003-11-20 | 2005-06-09 | Eli Lilly And Company | Vitamin d receptor modulators |
| DK1836151T3 (da) | 2004-12-21 | 2009-06-02 | Lilly Co Eli | D-vitamin-receptormodulatorer |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1511740T1 (sl) * | 2002-05-29 | 2009-12-31 | Lilly Co Eli | Modulatorji vitamin d receptorja tipa fenil-tiofen |
| DE60326082D1 (de) | 2002-11-22 | 2009-03-19 | Lilly Co Eli | Modulatoren von vitamin d rezeptoren |
| EP1587906A2 (en) * | 2003-01-10 | 2005-10-26 | Eli Lilly And Company | Vesicant treatment with phenyl-phenyl type vitamin d receptor modulators |
| WO2004063348A2 (en) * | 2003-01-10 | 2004-07-29 | Eli Lilly And Company | Vesicant treatment with phenyl-thiophene type vitamin d receptor modulators |
| ES2291981T3 (es) * | 2003-11-20 | 2008-03-01 | Eli Lilly And Company | Moduladores del receptor de la vitamina d. |
| US7595345B2 (en) | 2003-11-20 | 2009-09-29 | Eli Lilly And Company | Vitamin D receptor modulators |
| CA2544857A1 (en) * | 2003-11-20 | 2005-06-09 | Eli Lilly And Company | Vitamin d receptor modulators |
| WO2005051936A1 (en) * | 2003-11-20 | 2005-06-09 | Eli Lilly And Company | Phenyl-furan compounds as vitamin d receptor modulators |
| WO2005051898A2 (en) * | 2003-11-20 | 2005-06-09 | Eli Lilly And Company | Vitamin d receptor modulators |
| DK1836151T3 (da) | 2004-12-21 | 2009-06-02 | Lilly Co Eli | D-vitamin-receptormodulatorer |
-
2005
- 2005-12-19 CA CA002589667A patent/CA2589667A1/en not_active Abandoned
- 2005-12-19 ES ES05854993T patent/ES2369510T3/es not_active Expired - Lifetime
- 2005-12-19 KR KR1020077013993A patent/KR100931777B1/ko not_active Expired - Fee Related
- 2005-12-19 JP JP2007547045A patent/JP2008524260A/ja not_active Withdrawn
- 2005-12-19 US US11/721,676 patent/US7659296B2/en not_active Expired - Fee Related
- 2005-12-19 EP EP05854993A patent/EP1836177B1/en not_active Expired - Lifetime
- 2005-12-19 AT AT05854993T patent/ATE519755T1/de not_active IP Right Cessation
- 2005-12-19 WO PCT/US2005/046361 patent/WO2006069154A2/en not_active Ceased
- 2005-12-19 MX MX2007007225A patent/MX2007007225A/es active IP Right Grant
- 2005-12-19 BR BRPI0519152-1A patent/BRPI0519152A2/pt not_active IP Right Cessation
-
2007
- 2007-06-07 IL IL183779A patent/IL183779A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Xu et al. | Design, synthesis and biological evaluation of pyridine-chalcone derivatives as novel microtubule-destabilizing agents | |
| FI3578169T3 (fi) | Farmaseuttiset valmisteet, jotka käsittävät 4-{(1 r)-2-[(6-{2-[(2,6-diklooribentsyyli)oksi]etoksi}heksyyli)amino]-1-hydroksietyyli}-2-(hydroksimetyyli)fenolia | |
| EP2744773B1 (en) | Fluorinated bisphenol ether compounds and methods for their use | |
| TWI515184B (zh) | 紫杉烷衍生物製備改良方法 | |
| JP2008524260A5 (https=) | ||
| WO1982001188A1 (en) | 4,5-deoxymaytansinoide compounds and process for preparing same | |
| JPWO2021020429A1 (ja) | Ｌｐａ１受容体を拮抗するウレア化合物 | |
| CN101811968B (zh) | 多官能团化苯甲酰甲酸羟基酮酯类化合物及含有该类化合物的光引发剂 | |
| TW200732838A (en) | Salt suitable for an acid generator and a chemically amplified resist composition containing the same | |
| CN103421069A (zh) | 氟维司群磷酸酯衍生物及其制备方法和应用 | |
| AU2007262621A1 (en) | SHIP 1 modulator compounds | |
| JP2008524259A5 (https=) | ||
| US20240390504A1 (en) | Multifunctional conjugates | |
| US20210085640A1 (en) | Acylated catechin polyphenols and methods of their use for the treatment of cancer | |
| CA2544501A1 (en) | Vitamin d receptor modulators | |
| CA2506891A1 (en) | Vitamin d receptor modulators | |
| Lu et al. | Discovery of EBI-1051: a novel and orally efficacious MEK inhibitor with benzofuran scaffold | |
| CA2502293A1 (en) | Ship 1 modulators | |
| AR048899A1 (es) | Formulaciones en polvo para la inhalacion, las cuales contienen beta-agonistas enantiomericamente puros | |
| CA2546729A1 (en) | Phenyl-furan compounds as vitamin d receptor modulators | |
| NZ570711A (en) | 2-Substituted-1alpha, 25-dihydroxy-19,26,27-trinor vitamin D analogs and uses thereof | |
| JP2009502986A (ja) | エリアニン塩及びその調製方法、並びにそれを含む薬物組成物 | |
| RU2428427C2 (ru) | Стероидные соединения в качестве ингибиторов стероидсульфатазы | |
| CN102796134B (zh) | 一种马沙骨化醇中间体的制备方法 | |
| ES2396524B2 (es) | Intermedios versátiles y funcionalizados en la síntesis de vitamina D y nuevos derivados de vitamina D |